Get the Stockscreener App
8.64
3.25%
-0.29
After Hours:
8.64
4 D Molecular Therapeutics Inc stock is traded at $8.64, with a volume of 672.34K.
It is down -3.25% in the last 24 hours and up +2.98% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$8.93
Open:
$8.66
24h Volume:
672.34K
Relative Volume:
0.74
Market Cap:
$440.71M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-3.2481
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-10.56%
1M Performance:
+2.98%
6M Performance:
+18.84%
1Y Performance:
+107.69%
1-Day Range:
$8.42
$8.77
1-Week Range:
$8.3785
$9.74
52-Week Range:
$2.235
$12.34
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
8.64 | 455.50M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Nov-07-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
FDMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? - Yahoo Finance
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%Time to Buy? - MarketBeat
Key Catalysts on the Horizon for 4D Molecular Therapeutics - AD HOC NEWS
4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on Friday - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
Biotech 4DMT heads to three March healthcare investor conferences - Stock Titan
Janus Henderson (FDMT) reports 8.1% beneficial ownership in 4D Molecular Therapeutics - Stock Titan
4DMT Announces New Employment Inducement Grants - The Manila Times
Biotech 4DMT hands 124,200 stock units to just nine recruits - Stock Titan
4D Molecular Therapeutics Advances Toward Phase 3 Milestones in Retina Gene Therapy - AD HOC NEWS
Barclays flags M&A tailwinds and pricing relief as upside catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - MSN
Will 4D Molecular Therapeutics Inc. stock attract ESG investorsJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - mfd.ru
Will 4D Molecular Therapeutics Inc. benefit from geopolitical trends2025 Institutional Moves & Smart Allocation Stock Reports - mfd.ru
What are analysts’ price targets for 4D Molecular Therapeutics Inc.2025 Support & Resistance & Entry Point Strategy Guides - mfd.ru
4D Molecular (FDMT) Completes Enrollment for Key Phase 3 Wet AMD Trial - GuruFocus
What is 4D Molecular Therapeutics Inc. s debt to equity ratioEarnings Recap Summary & Reliable Price Breakout Alerts - mfd.ru
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD - Yahoo Finance
4D Molecular Therapeutics Completes Enrollment in Late-Stage Study of 4D-150 in Wet AMD - marketscreener.com
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - Finviz
Barclays Initiates Coverage of 4D Molecular Therapeutics (FDMT) with Overweight Recommendation - Nasdaq
Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga
4D Molecular Therapeutics Restructures Equity via Warrant Exchange - TipRanks
4D Molecular Therapeutics: A Valuation Disconnect Amidst Clinical Progress - AD HOC NEWS
4D Molecular (FDMT) Grants RSUs to New Employees - GuruFocus
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees - Intellectia AI
Biotech 4DMT hands 23,600 stock units to four new hires under award plan - Stock Titan
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Update - MarketBeat
FDMT: 4D-150 gene therapy shows strong safety, efficacy, and commercial potential in retinal disease - TradingView
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is 4D Molecular Therapeutics Inc. stock ready for breakoutJuly 2025 Intraday Action & Fast Moving Stock Trade Plans - ulpravda.ru
Is 4D Molecular Therapeutics Inc. stock a buy on dipsJuly 2025 Setups & Free Long-Term Investment Growth Plans - Улправда
Why 4D Molecular Therapeutics Inc. stock appeals to dividend seekersMarket Weekly Review & Low Drawdown Investment Strategies - Улправда
Stock Report: Can 4D Molecular Therapeutics Inc. stock double in next 5 years2025 Analyst Calls & Daily Technical Stock Forecast Reports - ulpravda.ru
Smart Money: Is 4D Molecular Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Trade Ideas & Free Reliable Trade Execution Plans - Улправда
Will 4D Molecular Therapeutics Inc. stock gain from strong economyJuly 2025 Outlook & High Return Stock Watch Alerts - ulpravda.ru
Can 4D Molecular Therapeutics Inc. stock double in next 5 yearsJuly 2025 Institutional & Risk Controlled Swing Alerts - Улправда
Is 4D Molecular Therapeutics Inc. stock a top momentum play2025 Volatility Report & High Accuracy Swing Trade Signals - Улправда
Los Angeles Daily News4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics, Inc. Announces Executive Changes - marketscreener.com
4DMT Provides Company Update and Anticipated Development Milestones for 2026 - The Manila Times
4D Molecular Therapeutics Announces Key Management Changes - TradingView — Track All Markets
One biotech’s 2026 push to change treatment for wet AMD and DME - Stock Titan
4D Molecular Therapeutics expands phase 3 trial enrollment - MSN
Certain Restricted Stock Units of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - MarketScreener
Certain Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com
4D Molecular falls after early-stage trial data for cystic fibrosis therapy - MSN
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Finviz
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):